Angioedema is a medical condition characterized by swelling beneath the skin or mucosa. The angioedema treatment market is driven by the increasing prevalence of angioedema, which can be caused by genetic factors, allergies, infections, and medications. The rising demand for effective treatment options, such as antihistamines, corticosteroids, and bradykinin receptor antagonists, is expected to boost the growth of the market. Additionally, the increasing awareness among patients and healthcare professionals about the diagnosis and management of angioedema is also expected to fuel market growth. However, the high cost of treatment and limited availability of approved drugs for some forms of angioedema may restrain market growth. Furthermore, adverse effects associated with some of the treatment options may also hinder market growth.
Key players in Angioedema Treatment Market include Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. In 2017, Shire plc. received European Commission (EC) approval for label extension, that increases indication for FIRAZYR (icatibant injection), broadening use to adolescents and children aged 2 years and older, with HAE caused by C1-esterase-inhibitor (C1-INH) deficiency.
Leading Companies in the Angioedema Treatment Industry:
1. Shire plc
Shire plc is a biopharmaceutical company headquartered in Dublin, Ireland. It was founded in 1986 and operates in over 70 countries worldwide. Shire is focused on developing treatments for rare diseases and has a portfolio of products for the treatment of hereditary angioedema (HAE), including Firazyr, Cinryze, and Takhzyro. In November 2022, Shire announced that it had submitted a Biologics License Application (BLA) to the US FDA for its HAE treatment product called SHP643.
2. CSL Limited
CSL Limited is a global biotechnology company headquartered in Melbourne, Australia. It was founded in 1916 and operates in over 60 countries worldwide. CSL's subsidiary, CSL Behring, produces HAE treatments, including Berinert and Haegarda. In January 2023, CSL Behring announced the approval of its HAE treatment, Haegarda, in Japan.
3. Pharming Group NV
Pharming Group NV is a biotech company headquartered in Leiden, the Netherlands. It was founded in 1988 and operates in various countries worldwide. The company's product, Ruconest, is approved for the treatment of acute HAE attacks in the United States, Europe, and other countries.
4. Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Carlsbad, California, United States. It was founded in 1989 and operates in various countries worldwide. Ionis is developing a product called AKCEA-APOCIII-LRx for the treatment of hereditary angioedema.
5. iBio Inc.
iBio Inc. is a biotechnology company headquartered in Bryan, Texas, United States. It was founded in 2008 and operates in various countries worldwide. The company is developing a product called IBIO-CFB03 for the treatment of HAE.
6. BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. is a biotech company headquartered in Durham, North Carolina, United States. It was founded in 1986 and operates in various countries worldwide. The company's HAE treatment product, Orladeyo, was approved by the FDA in 2020.
Definition- Angioedema treatment refers to medical interventions aimed at alleviating the symptoms and preventing the recurrence of angioedema, a condition characterized by the rapid swelling of the skin, mucosa, and submucosal tissues.
